KRAS G12D inhibitors in preclinical experiments demonstrate significant therapeutic potential by selectively targeting the mutant protein, showing robust antitumor activity including tumor regression in preclinical models, thereby offering a promising treatment strategy for patients with KRAS G12D-driven cancers that currently lack effective targeted therapies [340, 341]. Here, KRAS is linked to neoplasm.